KR900016211A - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number
KR900016211A
KR900016211A KR1019900005136A KR900005136A KR900016211A KR 900016211 A KR900016211 A KR 900016211A KR 1019900005136 A KR1019900005136 A KR 1019900005136A KR 900005136 A KR900005136 A KR 900005136A KR 900016211 A KR900016211 A KR 900016211A
Authority
KR
South Korea
Prior art keywords
compound
group
general formula
chloro
compound according
Prior art date
Application number
KR1019900005136A
Other languages
English (en)
Other versions
KR0185378B1 (ko
Inventor
시드니 오어레크 배리
마아크 브로밋지 스티븐
댑스 스티븐
Original Assignee
원본미기재
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898908365A external-priority patent/GB8908365D0/en
Priority claimed from GB898923299A external-priority patent/GB8923299D0/en
Application filed by 원본미기재, 비이참 그루우프 피이엘시이 filed Critical 원본미기재
Publication of KR900016211A publication Critical patent/KR900016211A/ko
Application granted granted Critical
Publication of KR0185378B1 publication Critical patent/KR0185378B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

신규 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(I)의 화합물 또는 제약학적으로 허용가능한 그들의 염.
    상기식에서 R1은
    (여기서, 각 p와 q는 독립적으로 2-4의 정수를 나타내고, r은 2-4의 정수를 나타내고, S는 1 또는 2를 나타내고, t는 0 또는 1을 나타냄)을 나타내고; R2는 기 OR4(여기서, R4는 C1-4알킬, C2-4알케닐, C2-4알키닐임), 기 OCOR5(여기서, R5는 수소 또는 R1임) 또는 기 NHR6또는NR7R8(여기서, R6, R7및 R8은 독립적으로 C1-2알킬임)이고; R2는 클로로, 플루오로, 브로모, 시클로프로필, 1-3의 할로겐원자로 치환된 C1-3알킬 이거나, R3는 기(CH2)nR9기 (여기서, R9은 -CN, -OH, -OCH3, -SH, -SCH3, -C=CH 또는 -CH=CH2이고 n은 0 또는 1이며, 단 n이 0일때, R9는 -OH 또는 -SH가 아님)이다.
  2. 제1항에 있어서, p가 2를 나타내고, q는 2 또는 3을 나타내거나, 조합(r,s,t)가 값(2, 2, 0), (2, 1, 1), (3, 1, 1), (2, 1, 0) 또는 (3, 1, 0)을 취한 화합물.
  3. 제1항 또는 제2항에 있어서, R2가 메톡시, 에톡시, 아릴옥시, 프로파르길옥시, 아세톡시 또는 디메틸아미노인 화합물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, R3가 시클로프로필, 클로로, 플루오로, 브로모, CN, OCH3, -C≡CH 또는 -CH2CN인 화합물.
  5. 또는 임의의 전술한 화합물의 제약학적으로 허용가능한 염.
  6. (a) 일반식(II) :
    (여기서, R1및 R3는 제1항에서 정의된 대로임)의 화합물을 일반식(III) :
    R´2-NH2(III)
    (여기서, R´2는 R2제1항에서 정의된 대로임) 또는 히드록시를 나타내고, R´3는 R3또는 그들로 전환가능한 기임)의 화합물과 반응시키고, R´2를 히드록시일때, R2로 전환시키고, R´3를 R3가 아닐때 R3로 전환시키고난후, 임의로 제약학적으로 허용가능한 염을 제조하거나: (b) 일반식(IV) :
    (여기서, R1는 R2(제1항에서 정의된 대로임)의 화합물을 R´3친핵제를 생성시킬 수 있는 일반식(V) :
    M-R´3(V)
    (여기서, R´3는 R3(제1항에서 정의된 대로임)또는 그들로 전환가능한 기임)의 화합물과 반응시키고 R´3를 R3가 아닐때, R3로 전환시키고 난후, 임의로 제약학적으로 허용가능한 염을 제조하거나: (c) 일반식(IVa) :
    (여기서, R1및 R2는 제1항에서 정의된 대로임)의 화합물을 염소화제, 브롬화제 또는 불소화제와 반응시키고, R3를 클로로 또는 브로모일때 임의로 다른 R3로 전환시키고 난후, 임의로 제약학적으로 허용가능한 염을 제조하는 것으로 구성된, 제1항의 화합물 또는 제약학적으로 허용가능한 그들의 염의 제조방법.
  7. 하기 일반식(IIb)의 화합물 또는 그들의 염 :
    상기식에서 R1및 R3는 제1항에서 정의된 대로이고, R3는 클로로 또는 브로모메틸이외의 것이다.
  8. 하기 일반식(IVa)의 화합물 :
    상기식에서, R1및 R2는 제1항에서 정의된 대로이다.
  9. 하기 일반식(IIb)의 화합물 :
    상기식에서, R´2는 R2또는 히드록시를 나타내고 R´3는 R3또는 그들로 전환가능한 기를 나타내고, R1, R2및 R3는 제1항에서 정의된 대로이며, 단 R´3가 R3일때, R´2는 R2가 아니다.
  11. 제1항에 따른 화합물 및 제약학적으로 허용가능한 담체로 구성된 제약학적 조성물.
  12. 활성 치료 물질로 사용하기 위한 제1항에 따른 화합물.
  13. 치매 치료 및/또는 예방에 사용하기위한 제1항에 따른 화합물.
  14. 치매 치료 및/또는 예방을 위한 의약 제조를 위한 제1항에 따른 화합물의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900005136A 1989-04-13 1990-04-13 신규 아자비시클릭 화합물, 그의 용도 및 제조방법 KR0185378B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB8908365.3 1989-04-13
GB89083653 1989-04-13
GB898908365A GB8908365D0 (en) 1989-04-13 1989-04-13 Novel compounds
GB8923299.5 1989-10-16
GB898923299A GB8923299D0 (en) 1989-10-16 1989-10-16 Novel compounds

Publications (2)

Publication Number Publication Date
KR900016211A true KR900016211A (ko) 1990-11-12
KR0185378B1 KR0185378B1 (ko) 1999-05-01

Family

ID=26295213

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900005136A KR0185378B1 (ko) 1989-04-13 1990-04-13 신규 아자비시클릭 화합물, 그의 용도 및 제조방법

Country Status (13)

Country Link
US (1) USRE35593E (ko)
EP (1) EP0392803B1 (ko)
JP (3) JP2665818B2 (ko)
KR (1) KR0185378B1 (ko)
AT (1) ATE269330T1 (ko)
CA (1) CA2014379C (ko)
DE (1) DE69034146T2 (ko)
DK (1) DK0392803T3 (ko)
ES (1) ES2219636T3 (ko)
HK (1) HK1012365A1 (ko)
NZ (1) NZ233290A (ko)
PT (1) PT93753B (ko)
SG (1) SG48315A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003435A1 (en) * 1990-08-24 1992-03-05 Beecham Group Plc Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9019095D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5356914A (en) * 1990-10-12 1994-10-18 Beecham Group P.L.C. 1,2,5,6-tetrahydropyridine oxime derivatives
WO1992011261A1 (en) * 1990-12-21 1992-07-09 Merck Sharp & Dohme Limited 4-azatricyclo[2.2.1.02,6]heptanes and pharmaceutical compositions
MX9300875A (es) 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
AU722015B2 (en) * 1996-05-13 2000-07-20 Zeneca Limited Bicyclic amines
GB9615628D0 (en) * 1996-07-25 1996-09-04 Smithkline Beecham Plc Formulation
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US6284771B1 (en) * 1997-04-11 2001-09-04 Eli Lilly And Company Method for treating schizophrenia
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
KR20030021641A (ko) * 2001-09-07 2003-03-15 안병로 투명비누 자가제조용 키트 및 상기 키트를 이용한투명비누 자가제조방법
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR102287645B1 (ko) 2018-12-18 2021-08-06 한화솔루션 주식회사 실리카계 촉매를 이용한 배위-음이온 개환 중합에 의한 폴리아마이드의 제조방법 및 이에 의해 제조된 폴리아마이드

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU563225B2 (en) * 1982-04-14 1987-07-02 Alizyme Therapeutics Limited I-aza bicyclic compounds
FR2531955A1 (fr) * 1982-08-17 1984-02-24 Pharmuka Lab Nouveau procede de preparation de derives de la quinuclidine substitues en position 3
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
DE3789039T2 (de) * 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
GB8615785D0 (en) * 1986-06-27 1986-08-06 Beecham Group Plc Compounds
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
ATE133415T1 (de) * 1987-04-15 1996-02-15 Beecham Group Plc Am brückenkopf substituierte azabicyclenderivate
IT1203971B (it) * 1987-04-24 1989-02-23 Roussel Maestretti Spa Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti
IT1222529B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropirdin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IT1222526B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropiridin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
DE3738521C1 (de) * 1987-11-13 1988-12-01 Delta Getriebe Gmbh Planetengetriebe
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
IT1233446B (it) * 1987-12-30 1992-04-01 Roussel Maestretti Spa Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
EP0338723B1 (en) * 1988-04-15 1993-08-04 Beecham Group Plc Novel compounds
IT1227436B (it) * 1988-10-28 1991-04-11 Roussel Maestretti Spa Derivati di 1-azabicicloalcani, loro procedimento di preparazione e loro applicazione come farmaci
US4937239A (en) * 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
EP0402056A3 (en) * 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2665818B2 (ja) 1997-10-22
DK0392803T3 (da) 2004-10-18
JPH09188679A (ja) 1997-07-22
AU619969B2 (en) 1992-02-06
CA2014379C (en) 2000-02-08
PT93753A (pt) 1990-11-20
JPH037285A (ja) 1991-01-14
NZ233290A (en) 1992-06-25
JPH09188678A (ja) 1997-07-22
EP0392803B1 (en) 2004-06-16
EP0392803A1 (en) 1990-10-17
ES2219636T3 (es) 2004-12-01
JP2913466B2 (ja) 1999-06-28
USRE35593E (en) 1997-08-19
DE69034146D1 (de) 2004-07-22
CA2014379A1 (en) 1990-10-13
AU5315990A (en) 1990-10-18
DE69034146T2 (de) 2005-07-14
SG48315A1 (en) 1998-04-17
PT93753B (pt) 1996-08-30
ATE269330T1 (de) 2004-07-15
JP2913467B2 (ja) 1999-06-28
KR0185378B1 (ko) 1999-05-01
HK1012365A1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
KR900016211A (ko) 신규 화합물
KR900700494A (ko) 마크로시클릭 화합물
MY129970A (en) Hypolipidaemic compounds
YU84791A (sh) Biciklicni 1-aza-cikloalkalni
NL300396I1 (nl) Nieuwe derivaten met naftalinestructuren, werkwijze voor de bereiding ervan en de farmaceutische preparaten die deze bevatten
FI904850A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 24-homo-D-vitamiinijohdannaisten valmistamiseksi
GB8919417D0 (en) Novel compounds
KR890005143A (ko) 17위치에서 3,4 또는 6개의 결합을 갖는 스피로 고리를 함유한 신규 스테로이드, 그의 제조 방법 및 제조용 중간체, 의약품으로서 그의 용도 및 이것을 함유하는 제약조성물.
ATE73780T1 (de) Glutaminsaeure-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische formulierungen.
HUT59377A (en) Process for producing drugs containing new aromatic rings
DE69831121D1 (de) Naphthalen Verbindungen, Verfahren zu deren Herstellung und deren pharmazeutischen Zusammensetzungen
SE8604950L (sv) Demensforbettrande och terapeutiska medel
DE68917772D1 (de) 2-Alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische Zusammensetzungen.
HUT52521A (en) Process for producing estremustine-esters and pharmaceutical compositions containing them as active components
DE3854684D1 (de) Cephalosporinverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate.
KR930700493A (ko) 신규의 옥사졸 유도체, 그의 제조방법 및 그를 함유하는 약제조성물
DE68928767D1 (de) Imido-percarbonsäuren
GR3033175T3 (en) Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them
GB914785A (en) Piperidine ester derivative

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111129

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 15

EXPY Expiration of term